Experimental immune therapy aims to tackle HPV cancers before standard care
NCT ID NCT05639972
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced HPV-positive cancers of the cervix, throat, anus, or other sites. The goal is to see if this approach is feasible and safe, and whether it improves tumor response and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- E7 TCR-T cells (a type of immune cell therapy) plus aldesleukin (a drug to boost immune response)
- What this could lead to
- If it works, this approach could shrink or eliminate HPV-related tumors before standard therapy, potentially improving long-term survival.
- What could go wrong
- This is a very early (Phase 1/2) feasibility study with only 15 participants. The treatment may cause serious side effects from the conditioning chemo or aldesleukin, and it may not shrink tumors effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RWJBarnabas Health - Robert Wood Johnson University Hospital
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy drug boost the power of chemoradiation against anal cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can less radiation be safer for throat cancer?
- Can a Two-Antibody combo outsmart advanced cancer?